ROCHE MUST DIVEST EUROPEAN COBAS MIRA CHEMISTRY ANALYZER BUSINESS UNDER CORANGE MERGER, EU SAYS; COMMISSION ALSO ORDERS LIBERALIZED PCR LICENSING
This article was originally published in The Gray Sheet
Executive Summary
Roche will have to divest its European Cobas Mira clinical chemistry business and liberalize its licensing of polymerase chain reaction technology to proceed with its acquisition of Corange Group companies Boehringer Mannheim and DePuy, the European Commission decided Feb. 4.